Genentech is paying $850 million upfront for Regor Pharmaceuticals’ portfolio of CDK inhibitors, taking ownership of a breast cancer candidate that has shown signs of single-agent efficacy in patients ...
Prognostic value of serum apolipoprotein B (ApoB) to apolipoprotein A-I (ApoA-I) ratio in hepatocellular carcinoma patients with transcatheter arterial chemoembolization treatment: propensity ...
HOFFMAN ESTATES, Ill.--(BUSINESS WIRE)--CDK Global, Inc. (Nasdaq: CDK), a leading retail automotive technology company, today introduced CDK ServiceView, a video and communications tool powered by ...
TACTIVE-K: Phase 1b/2 study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results